Literature DB >> 1776263

Absorption and disposition of epithiosteroids in rats (2): Avoidance of first-pass metabolism of mepitiostane by lymphatic absorption.

T Ichihashi1, H Kinoshita, H Yamada.   

Abstract

1. Absorption of mepitiostane (MP) from the gastrointestinal tract was examined using thoracic duct-cannulated rats. 2. When 14C-MP was administered into the small intestine, 34% of the radioactivity was recovered in the 6-h thoracic duct lymph. More than 90% of this radioactivity was due to unchanged MP and most of the MP in the lymph was carried in the lipid core of the chylomicrons and VLDL. 3. Radioactivity in the portal blood was extensively extracted by the liver and excreted into bile as polar metabolites. Thus, most unchanged MP which entered the systemic circulation following oral administration was drug absorbed via the intestinal lymphatics. 4. MP avoids the first-pass effect by lymphatic adsorption.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1776263     DOI: 10.3109/00498259109039527

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  4 in total

Review 1.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

2.  Intrinsic lymphatic partition rate of mepitiostane, epitiostanol, and oleic acid absorbed from rat intestine.

Authors:  T Ichihashi; H Kinoshita; Y Takagishi; H Yamada
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

3.  Factors determining the intrinsic lymphatic partition rate of epitiostanol and mepitiostane.

Authors:  T Ichihashi; Y Takagishi; H Yamada
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

Review 4.  Sulfated and Sulfur-Containing Steroids and Their Pharmacological Profile.

Authors:  Tatyana A Pounina; Tatyana A Gloriozova; Nick Savidov; Valery M Dembitsky
Journal:  Mar Drugs       Date:  2021-04-24       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.